Efficacy of micronized flavonoid fraction in healing of clean and infected wounds

Balas P, Pagratis N (1989) Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency. Int Angiol 8(4 Suppl):51–52.

Barbe R, Amiel M (1992) Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology Suppl 2:41–44.

Behar A, Lagrue G, Cohen-Boulakia F, Baillet J (1988) Capillary filtration in idiopathic cyclic edema—effects of Daflon 500 mg. Nuklear Medizin 27(3):105–107.

Bouskela E, Cyrino FZ, Lerond L (1997) Microvascular reactivity after ischemia/reperfusion in the hamster cheek pouch: beneficial effects of different oral doses of S-5682 (Daflon 500 mg). Angiology 48(1):33–37.

Bouskela E, Donyo KA (1997) Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 48(5):391–399.

Bouskela E, Svensjo E, Cyrino FZ, Lerond L (1997) Oxidant-induced increase in vascular permeability is inhibited by oral administration of S-5682 (Daflon 500 mg) and alpha-tocopherol. Int J Microcirc Clin Exp 17 Suppl 1:18–20.

Carrico TJ, Mehrhof AI Jr, Cohen IK (1984) Biology of wound healing. Surg Clin North Am 64:721–733.

Cypriani B, Limasset B, Carrie ML, Le Doucen C, Roussie M, De Paulet AC, Damon M (1993) Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol 45(7):1531–1535.

Di Perri T, Auteri A (1988) Action of S5682 on the complemant system (in vitro and in vivo study). Inter Angio 7(Suppl 2):11–15.

Friesenecker B, Tsai AG, Allegra C, Intaglietta M (1994) Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold. Int J Microcirc Clin Exp 14 (1–2):50–55.

Guillot B (1994) Techniques used to evaluate the cutaneous microcirculation: application of photoplethysmography to the assessment of a phlebotropic agent in the treatment of leg ulcers. Angiology 45(6 Pt 2):542–548.

Guilhou JJ, Fevrier F, Debure C, Dubeaux D, Gillet-Terver MN, Guillot B, Levesque H, Marzin L, Mignot J, Ouvry P, Pillion G, Van Landuyt H, Zuccarelli F, Nicolaides AN (1997) Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int J Microcirc Clin Exp 17 Suppl 1:21–26.

Hasanoglu (Arab) A, Orakci V, Erbilen M, Sahin M (1994) Wound healing. Turgut Ozal Med Cent 1(2):19–26.

Hogg JC (1994) Felix Fleischner Lecture. The traffic of polymorphonuclear leucoytes through pulmonary microvessels in health and disease. Am J Roentgenol 163:769–775.

Korthuis RJ, Gute DC (1997) Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc Clin Exp 17 Suppl 1:11–17.

Korthuis RJ, Gute DC (1999) Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc Res 36 (Suppl 1):15–23.

Labrid C (1994) Pharmacologic properties of Daflon 500 mg. Angiology 45(6 Pt 2):524–530.

Labrid CL, Perdrix L (1992) Mechanism of oedema: Activity of Daflon 500 mg. Phlebology Suppl 2:30–36.

Le Devehat C, Khodabandehlou T, Vimeux M, Kempf (1997) Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 17 Suppl 1:27–33.

Lonchampt M, Guardiola B, Sicot N, Bertrand M, Perdrix L, Duhault J (1989) Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. Arzneimittelforschung 39(8):882–885.

Nolte D, Pickelman S, Schutze E, Mollman M, Messmer K (1997) Effects of Daflon 500 mg on postischemic macromolecular leak syndrome in striated skin muscle of the hamster. Int J Microcirc Clin Exp 17 Suppl 1:6–10.

Pecking AP, Fevrier B, Wargon C, Pillion G (1997) Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 48(1):93–98.

Stucker O, Bonhomme E, Lenaers A, Teisseire B (1989) Daflon 500 mg depresses bradykinin-ischemia-induced microvascular leakage of FITC dextran in rat cremaster muscle. Int Angiol 8(4 Suppl):39–43.

Struckmann JR, Nicolaides AN (1994) Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 45(6):419–428.

Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, Hara A, Sumida T, Tanaka T, Ogawa H (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 18(5):957–965.

Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, Hara A, Sumida T, Tanaka T, Ogawa H (1997) Modulation of N-methyl-N-amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination. Carcinogenesis 18(4):761–769.

Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, Hara A, Sumida T, Fukutani K, Tanaka T, Ogawa H (1997) Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res 15;57(2):246–252.

Tsouderos Y (1989) Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Int Angiol 8(4 Suppl):53–59.

Tsouderos Y (1991) Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol 80 Suppl 7:95–101.